WTA
FLNA

Washington Trust Advisors’s Filana Therapeutics FLNA Stock Holding History

Washington Trust Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-75
Closed -$2.21K – 683
2024
Q3 		$2.21K Hold
75
– – ﹤0.01% 632
2024
Q2 		$927 Hold
75
– – ﹤0.01% 653
2024
Q1 		$1.52K Hold
75
– – ﹤0.01% 646
2023
Q4 		$1.69K Buy
+75
New +$1.58K ﹤0.01% 646

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Washington Trust Advisors's FLNA Position: Q4 2024 in Review

Washington Trust Advisors sold out of Filana Therapeutics (FLNA) in Q4 2024, closing a stake of 75 shares — an estimated $2.21K sold.

Washington Trust Advisors first reported a position in FLNA in Q4 2023 and held it in 4 quarters. The position peaked at $2.21K in Q3 2024. 137 funds tracked by Wall St. Rank hold FLNA as of Q4 2024.

  • Washington Trust Advisors reported no remaining Filana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Washington Trust Advisors sold 75 Filana Therapeutics shares in Q4 2024, an estimated $2.21K.
  • Washington Trust Advisors first reported a position in Filana Therapeutics in Q4 2023 and held it in 4 quarters.
  • Washington Trust Advisors's Filana Therapeutics position peaked at $2.21K in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2024.

Based on Washington Trust Advisors's 13F filing for Q4 2024, filed 6 Feb 2025.